SG11201706445SA - Enhanced delivery of viral particles to the striatum and cortex - Google Patents
Enhanced delivery of viral particles to the striatum and cortexInfo
- Publication number
- SG11201706445SA SG11201706445SA SG11201706445SA SG11201706445SA SG11201706445SA SG 11201706445S A SG11201706445S A SG 11201706445SA SG 11201706445S A SG11201706445S A SG 11201706445SA SG 11201706445S A SG11201706445S A SG 11201706445SA SG 11201706445S A SG11201706445S A SG 11201706445SA
- Authority
- SG
- Singapore
- Prior art keywords
- striatum
- cortex
- viral particles
- enhanced delivery
- enhanced
- Prior art date
Links
- 210000001577 neostriatum Anatomy 0.000 title 1
- 239000002245 particle Substances 0.000 title 1
- 230000003612 virological effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562114544P | 2015-02-10 | 2015-02-10 | |
| US201562220997P | 2015-09-19 | 2015-09-19 | |
| PCT/US2016/017210 WO2016130591A2 (fr) | 2015-02-10 | 2016-02-09 | Administration améliorée de particules virales au striatum et au cortex |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201706445SA true SG11201706445SA (en) | 2017-09-28 |
Family
ID=56614902
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201907399RA SG10201907399RA (en) | 2015-02-10 | 2016-02-09 | Enhanced delivery of viral particles to the striatum and cortex |
| SG11201706445SA SG11201706445SA (en) | 2015-02-10 | 2016-02-09 | Enhanced delivery of viral particles to the striatum and cortex |
| SG10201912926VA SG10201912926VA (en) | 2015-02-10 | 2016-02-10 | Enhanced delivery of viral particles to the striatum and cortex |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201907399RA SG10201907399RA (en) | 2015-02-10 | 2016-02-09 | Enhanced delivery of viral particles to the striatum and cortex |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912926VA SG10201912926VA (en) | 2015-02-10 | 2016-02-10 | Enhanced delivery of viral particles to the striatum and cortex |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20190111157A1 (fr) |
| EP (3) | EP4219728A3 (fr) |
| JP (3) | JP6928558B2 (fr) |
| KR (2) | KR102625784B1 (fr) |
| CN (2) | CN107530447A (fr) |
| AU (2) | AU2016219398A1 (fr) |
| BR (1) | BR112017017037A2 (fr) |
| CA (1) | CA2976082A1 (fr) |
| CL (1) | CL2017002028A1 (fr) |
| CR (1) | CR20170407A (fr) |
| DK (1) | DK3256594T3 (fr) |
| EA (1) | EA201791803A1 (fr) |
| ES (1) | ES2904504T3 (fr) |
| HK (1) | HK1246340A1 (fr) |
| HU (1) | HUE057272T2 (fr) |
| IL (3) | IL296466A (fr) |
| LT (1) | LT3256594T (fr) |
| MX (2) | MX2017010370A (fr) |
| PH (1) | PH12017501436A1 (fr) |
| PL (1) | PL3256594T3 (fr) |
| PT (1) | PT3256594T (fr) |
| RS (1) | RS62811B1 (fr) |
| SG (3) | SG10201907399RA (fr) |
| SI (1) | SI3256594T1 (fr) |
| TN (1) | TN2017000353A1 (fr) |
| TW (1) | TWI730952B (fr) |
| WO (1) | WO2016130591A2 (fr) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015191508A1 (fr) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Capsides chimériques |
| MX2017005834A (es) | 2014-11-05 | 2017-11-17 | Voyager Therapeutics Inc | Polinucleotidos aad para el tratamiento de la enfermedad de parkinson. |
| CN112375760A (zh) | 2014-11-14 | 2021-02-19 | 沃雅戈治疗公司 | 调节性多核苷酸 |
| AU2015346162B2 (en) | 2014-11-14 | 2022-02-10 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
| WO2016094783A1 (fr) | 2014-12-12 | 2016-06-16 | Voyager Therapeutics, Inc. | Compositions et méthodes pour la production de scaav |
| SG10201907399RA (en) * | 2015-02-10 | 2019-09-27 | Genzyme Corp | Enhanced delivery of viral particles to the striatum and cortex |
| TWI707951B (zh) | 2015-04-08 | 2020-10-21 | 美商健臻公司 | 過大腺相關載體之製造 |
| CA3019315A1 (fr) | 2015-04-23 | 2016-10-27 | University Of Massachusetts | Modulation de l'expression d'un transgene du vecteur aav |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| BR112018006074A2 (pt) | 2015-09-24 | 2018-10-09 | Biomarin Pharm Inc | vetores de fator viii de vírus adeno-associado, partículas virais associadas e formulações terapêuticas compreendendo as mesmas |
| WO2017189959A1 (fr) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions pour le traitement de maladies |
| EP3448987A4 (fr) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | Compositions pour le traitement de maladies |
| RU2764587C2 (ru) | 2016-05-18 | 2022-01-18 | Вояджер Терапьютикс, Инк. | Способы и композиции для лечения хореи гентингтона |
| SG11201809699XA (en) | 2016-05-18 | 2018-12-28 | Voyager Therapeutics Inc | Modulatory polynucleotides |
| US11298041B2 (en) | 2016-08-30 | 2022-04-12 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
| CN109863243B (zh) * | 2016-09-30 | 2023-07-28 | 埃斯蒂文制药股份有限公司 | 用于治疗粘多糖症的腺相关病毒载体 |
| EP3613856A4 (fr) * | 2017-03-31 | 2020-12-23 | Staidson(Beijing) Biopharmaceuticals Co., Ltd. | Cassette d'expression d'arn court en épingle à cheveux, séquence polynucléotidique la portant et application correspondante |
| WO2018191450A2 (fr) | 2017-04-14 | 2018-10-18 | National Taiwan University Hospital | Thérapie génique pour une carence en aadc |
| JP2020518258A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法 |
| SG11201909868YA (en) * | 2017-05-05 | 2019-11-28 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| CN111132626B (zh) | 2017-07-17 | 2024-01-30 | 沃雅戈治疗公司 | 轨迹阵列引导系统 |
| KR20200044793A (ko) | 2017-08-03 | 2020-04-29 | 보이저 테라퓨틱스, 인크. | Aav의 전달을 위한 조성물 및 방법 |
| JP2021502060A (ja) | 2017-10-16 | 2021-01-28 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 筋萎縮性側索硬化症（ａｌｓ）の治療 |
| WO2019079242A1 (fr) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | Traitement de la sclérose latérale amyotrophique (sla) |
| CN110876269B (zh) * | 2018-06-29 | 2021-07-30 | 武汉纽福斯生物科技有限公司 | 治疗遗传性视神经病变的组合物和方法 |
| MX2021005517A (es) * | 2018-11-14 | 2021-06-18 | Regenxbio Inc | Terapia genica para lipofuscinosis neuronal ceroidea. |
| US20220136008A1 (en) * | 2019-02-22 | 2022-05-05 | The Trustees Of The University Of Pennsylvania | Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration |
| EP3983077A4 (fr) * | 2019-06-17 | 2023-12-20 | Alnylam Pharmaceuticals, Inc. | Administration d'oligonucléotides au striatum |
| WO2021007382A1 (fr) * | 2019-07-09 | 2021-01-14 | Voyager Therapeutics, Inc. | Compositions et procédés pour le traitement de la maladie de parkinson |
| WO2021016505A1 (fr) * | 2019-07-24 | 2021-01-28 | Voyager Therapeutics, Inc. | Compositions et méthodes de traitement de la maladie de huntington |
| JPWO2021177116A1 (fr) * | 2020-03-02 | 2021-09-10 | ||
| WO2021183674A1 (fr) * | 2020-03-11 | 2021-09-16 | Remotor Therapeutics, Inc. | Procédés et matériaux de dissémination d'une protéine à travers le système nerveux central |
| CA3209471A1 (fr) * | 2021-01-27 | 2022-08-04 | Research Institute At Nationwide Children's Hospital | Materiels et methodes pour le traitement d'un deficit en lipase acide lysosomale (dlal) |
| WO2023113806A1 (fr) | 2021-12-16 | 2023-06-22 | Affinia Therapeutics, Inc. | Vaa recombinant pour le traitement d'une maladie neurale |
| WO2022221193A1 (fr) | 2021-04-12 | 2022-10-20 | Affinia Therapeutics Inc. | Aav recombinant pour le traitement d'une maladie neurale |
| WO2023108507A1 (fr) * | 2021-12-15 | 2023-06-22 | National Institute Of Biological Sciences, Beijing | Vecteurs aav recombinants et leur utilisation |
| WO2023109911A1 (fr) * | 2021-12-15 | 2023-06-22 | National Institute Of Biological Sciences, Beijing | Microglie ayant un car et son utilisation |
| WO2024086747A1 (fr) | 2022-10-19 | 2024-04-25 | Affinia Therapeutics Inc. | Aavs recombinants à tropisme et spécificité améliorés |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4692147A (en) | 1980-04-02 | 1987-09-08 | Medtronic, Inc. | Drug administration device |
| US5735815A (en) | 1993-07-26 | 1998-04-07 | Sentinel Medical, Inc. | Method of using fluid jet surgical cutting tool |
| WO1998010088A1 (fr) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Procede inductible de production de virus adeno-associes recombines au moyen de la polymerase t7 |
| US6042579A (en) | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
| US6995006B2 (en) | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| ATE316576T1 (de) * | 1998-05-27 | 2006-02-15 | Avigen Inc | Konvektion-erhöhte verabreichung aadc-kodierende aav vektoren |
| AU781958C (en) | 1999-08-09 | 2006-03-30 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs |
| ES2256265T3 (es) | 2000-06-01 | 2006-07-16 | University Of North Carolina At Chapel Hill | Vectores de parvovirus duplicados. |
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| NZ532635A (en) | 2001-11-13 | 2007-05-31 | Univ Pennsylvania | A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method |
| GB2389791B (en) | 2002-04-30 | 2006-12-13 | Steven Gill | Implantable drug delivery pump |
| PT1625210E (pt) | 2003-05-21 | 2011-03-15 | Genzyme Corp | Métodos para produzir preparações de vírions de aav recombinantes substancialmente livres de capsídeos vazios |
| CN102626336A (zh) | 2004-10-05 | 2012-08-08 | 建新公司 | 台阶式插管 |
| WO2006119432A2 (fr) | 2005-04-29 | 2006-11-09 | The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services | Isolation, clonage, et caracterisation de nouveaux serotypes de virus adeno-associes (avv) |
| US9089667B2 (en) | 2005-08-23 | 2015-07-28 | The Regents Of The University Of California | Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery |
| WO2007120542A2 (fr) | 2006-03-30 | 2007-10-25 | The Board Of Trustees Of The Leland Stanford Junior University | Bibliothèque de capsides aav et protéines de capsides aav |
| ES2618787T5 (es) | 2006-04-25 | 2022-10-21 | Univ California | Administración de factores de crecimiento para el tratamiento de trastornos del SNC |
| WO2007127839A2 (fr) | 2006-04-26 | 2007-11-08 | The Regents Of The University Of California | Compositions et méthodes pour l'administration de neurothérapeutiques de haut poids moléculaire améliorée par convection |
| WO2010088560A1 (fr) * | 2009-01-29 | 2010-08-05 | University Of California, San Francisco | Procédés de délivrance de taux élevés d'agents thérapeutiques dans la totalité du cortex pour le traitement des troubles neurologiques |
| HUE028341T2 (en) | 2009-06-16 | 2016-12-28 | Genzyme Corp | Improved methods for purifying recombinant AAV vectors |
| US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| EP2673286B1 (fr) * | 2011-02-12 | 2019-07-03 | University of Iowa Research Foundation | Composés thérapeutiques |
| BR112013020734A2 (pt) | 2011-02-17 | 2017-06-13 | Univ Pennsylvania | composições e métodos para alterar a especificidade do tecido e aprimorar a transferência gênica mediada por aav9 |
| HUE054768T2 (hu) * | 2014-05-02 | 2021-09-28 | Genzyme Corp | AAV vektorok retina és CNS génterápiára |
| SG10201907399RA (en) * | 2015-02-10 | 2019-09-27 | Genzyme Corp | Enhanced delivery of viral particles to the striatum and cortex |
-
2016
- 2016-02-09 SG SG10201907399RA patent/SG10201907399RA/en unknown
- 2016-02-09 JP JP2017560479A patent/JP6928558B2/ja active Active
- 2016-02-09 MX MX2017010370A patent/MX2017010370A/es unknown
- 2016-02-09 EA EA201791803A patent/EA201791803A1/ru unknown
- 2016-02-09 TN TNP/2017/000353A patent/TN2017000353A1/en unknown
- 2016-02-09 SG SG11201706445SA patent/SG11201706445SA/en unknown
- 2016-02-09 KR KR1020177025285A patent/KR102625784B1/ko active IP Right Grant
- 2016-02-09 DK DK16714066.4T patent/DK3256594T3/da active
- 2016-02-09 CN CN201680020700.4A patent/CN107530447A/zh active Pending
- 2016-02-09 RS RS20220044A patent/RS62811B1/sr unknown
- 2016-02-09 CN CN202210805297.3A patent/CN116019934A/zh active Pending
- 2016-02-09 CA CA2976082A patent/CA2976082A1/fr active Pending
- 2016-02-09 BR BR112017017037A patent/BR112017017037A2/pt active Search and Examination
- 2016-02-09 CR CR20170407A patent/CR20170407A/es unknown
- 2016-02-09 PT PT167140664T patent/PT3256594T/pt unknown
- 2016-02-09 HU HUE16714066A patent/HUE057272T2/hu unknown
- 2016-02-09 KR KR1020247000976A patent/KR20240010539A/ko active Application Filing
- 2016-02-09 AU AU2016219398A patent/AU2016219398A1/en not_active Abandoned
- 2016-02-09 WO PCT/US2016/017210 patent/WO2016130591A2/fr active Application Filing
- 2016-02-09 SI SI201631446T patent/SI3256594T1/sl unknown
- 2016-02-09 US US15/549,962 patent/US20190111157A1/en not_active Abandoned
- 2016-02-09 LT LTEPPCT/US2016/017210T patent/LT3256594T/lt unknown
- 2016-02-09 EP EP23150591.8A patent/EP4219728A3/fr active Pending
- 2016-02-09 ES ES16714066T patent/ES2904504T3/es active Active
- 2016-02-09 IL IL296466A patent/IL296466A/en unknown
- 2016-02-09 EP EP21198081.8A patent/EP4023758A1/fr not_active Withdrawn
- 2016-02-09 EP EP16714066.4A patent/EP3256594B1/fr active Active
- 2016-02-09 PL PL16714066T patent/PL3256594T3/pl unknown
- 2016-02-10 SG SG10201912926VA patent/SG10201912926VA/en unknown
- 2016-02-15 TW TW105104342A patent/TWI730952B/zh active
-
2017
- 2017-08-08 CL CL2017002028A patent/CL2017002028A1/es unknown
- 2017-08-08 IL IL253894A patent/IL253894B/en unknown
- 2017-08-10 MX MX2021004294A patent/MX2021004294A/es unknown
- 2017-08-10 PH PH12017501436A patent/PH12017501436A1/en unknown
-
2018
- 2018-04-25 HK HK18105355.8A patent/HK1246340A1/zh unknown
-
2021
- 2021-07-22 IL IL285060A patent/IL285060B2/en unknown
- 2021-08-06 JP JP2021129519A patent/JP2021178861A/ja active Pending
-
2022
- 2022-06-28 AU AU2022204583A patent/AU2022204583A1/en active Pending
- 2022-07-29 US US17/816,139 patent/US20220395586A1/en active Pending
-
2023
- 2023-02-10 JP JP2023018846A patent/JP2023058630A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285060A (en) | Increased transmission of viral particles to the striatum and cortex | |
| IL258723A (en) | A particle and a system for creating a spray containing such particles | |
| HK1253018A1 (zh) | 紫杉烷顆粒及其用途 | |
| HK1255670A1 (zh) | Cmv的修飾病毒樣顆粒 | |
| IL259894A (en) | Improved compositions and improved methods for viral delivery of neoepitopes and their use | |
| ZA201704662B (en) | Friable ceramic-bonded diamond composite particles and methods to produce same | |
| IL260022A (en) | Preparation of respirable zafirlukast particles | |
| SG11201701669PA (en) | Flavivirus virus like particle | |
| ZA201605492B (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| HK1256875A1 (zh) | 加强對大腦的藥物輸送 | |
| EP3356472C0 (fr) | Traitement de surface de particules | |
| GB201522512D0 (en) | Flourescent diamond particles and methods of fabricating the same | |
| PL3233233T3 (pl) | Kompozycje odpieniające zawierające cząstki amfifilowe i sposoby ich stosowania | |
| SG11201704486TA (en) | Improvements in and relating to the treatment of matrices and/or the contents of matrices | |
| HK1248652A1 (zh) | 由漿滴製造支撐劑顆粒的方法及支撐劑顆粒的使用方法 | |
| IL256933B (en) | Cleaning particles and their use | |
| HK1254366A1 (zh) | 由漿滴形成的支撐劑顆粒及其使用方法 | |
| GB201421261D0 (en) | Improvements in and relating to the processing of matrices and/or the contents of matrices | |
| HUE061732T2 (hu) | Eljárás részecskék elõállítására | |
| GB201402556D0 (en) | Improvements relating to inhalable particles | |
| GB2545716B (en) | Improvements in or relating to the separation of radon | |
| GB201517790D0 (en) | Preparation of inhalable particles | |
| EP3359618A4 (fr) | Composites de sable et leurs procédés d'utilisation pour la lutte contre la poussière | |
| GB201520019D0 (en) | The genome and self-evolution of AI | |
| GB201504861D0 (en) | Viral particle based RNA Interaction Trap |